Arkolith/Insider Trading/XLO/Form 4

Russo Rene

PRESIDENT AND CEO, DirectorXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Jan 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 1, 2026Option exercise(M)44K——325K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 1, 2026Option exercise(M)44K—$089K
Dec 31, 2025Grant(A)1.5M—$01.5M

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-002512) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML